KRAS and neoplasm: The baseline patient and tumor characteristics of the developmental and validation cohorts were heterogeneous in terms of ICI agent; sex; histologic findings; tumor, sample type, and site; and EGFR and KRAS status; however, they were similar in risk factors that might influence ICI response—eg, treatment line, Eastern Cooperative Oncology Group (ECOG) performance status, age, and high (≥50%) PD-L1 expression (Table 1).